+

WO2008035230A3 - Compositions protéiques liquides - Google Patents

Compositions protéiques liquides Download PDF

Info

Publication number
WO2008035230A3
WO2008035230A3 PCT/IB2007/004181 IB2007004181W WO2008035230A3 WO 2008035230 A3 WO2008035230 A3 WO 2008035230A3 IB 2007004181 W IB2007004181 W IB 2007004181W WO 2008035230 A3 WO2008035230 A3 WO 2008035230A3
Authority
WO
WIPO (PCT)
Prior art keywords
substantially purified
liquid compositions
composition
purified igf
igf
Prior art date
Application number
PCT/IB2007/004181
Other languages
English (en)
Other versions
WO2008035230A2 (fr
Inventor
Tatyana Mitina
Geoffrey Francis
Original Assignee
Novozymes Gropep Ltd
Tatyana Mitina
Geoffrey Francis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novozymes Gropep Ltd, Tatyana Mitina, Geoffrey Francis filed Critical Novozymes Gropep Ltd
Publication of WO2008035230A2 publication Critical patent/WO2008035230A2/fr
Publication of WO2008035230A3 publication Critical patent/WO2008035230A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne une composition liquide comprenant un IGF sensiblement purifié, le pH de cette composition étant égal ou inférieur à 5,0. De préférence, le pH de cette composition est égal ou inférieur à 4,0. De préférence encore, le pH de cette composition est égal ou inférieur à 3,5. De préférence encore, le pH de cette composition est égal ou supérieur à 2,5. De préférence encore, le pH de cette composition est égal ou supérieur à 1,0. Dans un mode de réalisation préféré, le pH de la composition est compris entre 2,5 et 3,5. Par exemple, le pH de cette composition vaut 3,0, 3,1, 3,2, 3,4 ou 3,5.
PCT/IB2007/004181 2006-09-18 2007-09-18 Compositions protéiques liquides WO2008035230A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82596706P 2006-09-18 2006-09-18
US60/825,967 2006-09-18

Publications (2)

Publication Number Publication Date
WO2008035230A2 WO2008035230A2 (fr) 2008-03-27
WO2008035230A3 true WO2008035230A3 (fr) 2008-06-05

Family

ID=39200915

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2007/004181 WO2008035230A2 (fr) 2006-09-18 2007-09-18 Compositions protéiques liquides

Country Status (1)

Country Link
WO (1) WO2008035230A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015142A1 (fr) * 1989-06-09 1990-12-13 Gropep Pty. Ltd. Proteines de fusion pour hormones de croissance
WO1999024062A1 (fr) * 1997-11-07 1999-05-20 Chiron Corporation Nouvelle composition d'igf-i et son utilisation

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990015142A1 (fr) * 1989-06-09 1990-12-13 Gropep Pty. Ltd. Proteines de fusion pour hormones de croissance
WO1999024062A1 (fr) * 1997-11-07 1999-05-20 Chiron Corporation Nouvelle composition d'igf-i et son utilisation

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
"Sigma product catalog: Biochemicals and Reagents for Life Science Research 2002-2003", '12781, INSULIN-LIKE GROWTH FACTOR-II (DELTA 1-6) HUMAN' AND SIGMA PRODUCT INFORMATION SHEET 'INSULIN-LIKE GROWTH FACTOR-II (DELTA 1-6), HUMAN, RECOMBINANT. PRODUCT NO. I2781', August 2001 (2001-08-01) *
"Sigma product catalog: Biochemicals and Reagents for Life Science Research 2002-2003", I2139, INSULIN-LIKE GROWTH FACTOR-II HUMAN' AND SIGMA PRODUCT INFORMATION SHEET 'INSULIN-LIKE GROWTH FACTOR-II, HUMAN, RECOMBINANT. PRODUCT NO. I2139, September 2000 (2000-09-01) *
"Sigma product catalog: Biochemicals and Reagents for Life Science Research 2002-2003", 'I2526, INSULIN-LIKE GROWTH FACTOR-II HUMAN' AND SIGMA PRODUCT INFORMATION SHEET 'INSULIN-LIKE GROWTH FACTOR-II, HUMAN, RECOMBINANT. PRODUCT NO. I2526, October 2002 (2002-10-01) *
"Sigma product catalog: Biochemicals and REagents for Life Science Research 2002-2003", 'I2656, INSULIN-LIKE GROWTH FACTOR-I (E3R), HUMAN' AND SIGMA PRODUCT INFORMATION SHEET 'INSULIN-LIKE GROWTH FACTOR-I (E3R), HUMAN, RECOMBINANT PRODUCT NO. I2656, August 2001 (2001-08-01), pages 1114 *
"Sigma product catalog: Biochemicals and Reagents for Life Science Research 2002-2003", 'I8904, INSULIN-LIKE GROWTH FACTOR-II FROM MOUSE' AND SIGMA PRODUCT INFORMATION SHEET 'INSULIN-LIKE GROWTH FACTOR-II, MOUSE, RECOMBINANT. PRODUCT NO. I8904', May 2006 (2006-05-01), pages 1116 *
FRANCIS G.L. ET AL.: "Novel recombinant fusion protein analogues of insulin-like growth factor (IGF)-I indicate the relative importance of IGF-binding protein and receptor binding for enhanced biological potency", JOURNAL OF MOLECULAR ENDOCRINOLOGY, vol. 8, 1992, pages 213 - 223, XP000891905, DOI: doi:10.1677/jme.0.0080213 *
LIEN S. ET AL.: "Linkers for improved cleavage of fusion protein with an engineered alpha-lytic protease", BIOTECHNOLOGY AND BIOENGINEERING, vol. 74, no. 4, 2001, pages 335 - 343, XP003014121, DOI: doi:10.1002/bit.1124 *
POLYAK S.W. ET AL.: "Introduction of spacer peptides N-terminal to a cleavage recognition motif in recombinant fusion proteins can improve site-specific cleavage", PROTEIN ENGINEERING, vol. 10, no. 6, 1997, pages 615 - 619, XP055272527, DOI: doi:10.1093/protein/10.6.615 *

Also Published As

Publication number Publication date
WO2008035230A2 (fr) 2008-03-27

Similar Documents

Publication Publication Date Title
WO2006020768A3 (fr) Oligonucleotides chimiquement modifies
WO2007120980A3 (fr) Composés de 2,4-pyrimidinediamine pour le traitement ou la prévention de maladies autoimmunes
WO2007002204A3 (fr) Procedes de pyrosequencage et compositions associees
WO2007127841A3 (fr) Compositions et leurs méthodes d'élaboration
WO2007106436A3 (fr) Composes et compositions photoactifs et utilisations derivees
WO2007087259A9 (fr) Compositions contenant une enzyme et un agent de photoblanchiment
WO2008014008A3 (fr) Compositions et procédés pour moduler l'angiogenèse
MX286273B (es) Composiciones y metodos para inhibicion de la via jak.
WO2007130697A3 (fr) Anticorps anti-ephb4 et procedes qui les utilisent
WO2007019439A3 (fr) Compositions de copolymere sequence et utilisations de ces dernieres
WO2007092622A3 (fr) Compositions et méthodes pour le traitement d'os
WO2009077471A3 (fr) Azolylméthyloxiranes, leur utilisation et agents les contenant
WO2007127204A3 (fr) Méthodes et compositions concernant une immunostimulation
WO2007041282A3 (fr) Procedes et compositions destines au traitement de la fibrose kystique
WO2005117557A3 (fr) Systeme d'expression
WO2007127506A3 (fr) Anticorps anti-ephrinb2 et procédés les utilisant
WO2008033333A3 (fr) Variants de la famille il-1
WO2006133006A3 (fr) 1-methyl-1h-pyrazole-4-carboxamides utiles comme agents chimiotherapeutiques anticancereux
WO2007135562A3 (fr) Nouveaux dérivés d'hydroxyphényle et leurs applications biologiques
EP1969939A3 (fr) Compositions Nematicides
WO2006078998A3 (fr) Methodes et compositions permettant de reduire la production de salive
WO2007085728A3 (fr) Composition comprenant plusieurs toxines botuliques
WO2007132355A3 (fr) Compositions et procédés pour inhiber l'adhésion virale
WO2005074925A8 (fr) Compositions contenant de la piperacilline et du tazobactame
WO2009158387A3 (fr) Compositions, formulations, et procédés permettant de prévenir et/ou de traiter des effets physiques de la consommation d'alcool

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07859244

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07859244

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载